📊 BRTX Key Takeaways
Is BioRestorative Therapies, Inc. (BRTX) a Good Investment?
BioRestorative Therapies exhibits severe financial distress with massive operating losses (-$11.8M) against minimal revenue ($340.1K), indicating the company is burning cash at an unsustainable rate. With negative operating cash flow of -$8.4M, only $602.4K in cash reserves, and revenue declining 35.7% YoY, the company faces critical liquidity risk and potential insolvency without immediate capital injection or dramatic operational turnaround.
BioRestorative Therapies shows extremely weak fundamentals, with minimal revenue, deeply negative operating and net margins, and heavy cash burn relative to its asset base and cash position. While gross margin is high and leverage is low, the business currently lacks evidence of scalable commercialization and appears dependent on external financing to sustain operations.
Why Buy BioRestorative Therapies, Inc. Stock? BRTX Key Strengths
- Exceptional gross margin of 93.5% suggests underlying product economics could be viable if revenue scales
- Moderate debt-to-equity ratio of 0.11x indicates limited financial leverage and lower bankruptcy risk from debt obligations
- Current ratio of 1.37x provides minimal short-term liquidity cushion above critical threshold
- High gross margin indicates the limited revenue base is not constrained by direct production costs
- Balance sheet leverage is low, with modest long-term debt relative to equity
- Current and quick ratios above 1.0 suggest near-term liquidity is not yet fully impaired
BRTX Stock Risks: BioRestorative Therapies, Inc. Investment Risks
- Severe cash burn rate of -$8.4M operating cash flow against only $602.4K cash reserves indicates runway of approximately 2-3 months
- Collapsing revenue (-35.7% YoY) combined with fixed operating costs creates deteriorating unit economics and path to insolvency
- Massive negative profitability metrics (Operating Margin: -3476%, Net Margin: -3244%) demonstrate fundamental business model failure at current scale
- No insider buying activity in 90 days suggests lack of management confidence in company prospects
- Revenue declined 35.7% year over year, indicating weak and deteriorating commercial traction
- Operating loss of $11.82M and free cash flow of -$8.41M are far too large relative to $602.44K cash on hand
- Very negative ROE and ROA indicate severe capital inefficiency and ongoing shareholder dilution risk if funding is needed
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Revenue stabilization and return to growth trajectory
- Operating expense reduction and path to operating cash flow breakeven
- Success of capital raising efforts to extend liquidity
- Quarterly operating cash burn relative to cash balance
- Revenue growth and evidence of sustained commercialization
BioRestorative Therapies, Inc. (BRTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
BioRestorative Therapies, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BRTX Profit Margin, ROE & Profitability Analysis
BRTX vs Services Sector: How BioRestorative Therapies, Inc. Compares
How BioRestorative Therapies, Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioRestorative Therapies, Inc. Stock Overvalued? BRTX Valuation Analysis 2026
Based on fundamental analysis, BioRestorative Therapies, Inc. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioRestorative Therapies, Inc. Balance Sheet: BRTX Debt, Cash & Liquidity
BRTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BioRestorative Therapies, Inc.'s revenue has grown significantly by 421% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.16 indicates the company is currently unprofitable.
BRTX Revenue Growth, EPS Growth & YoY Performance
BRTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.8K | -$1.1M | $-0.13 |
| Q2 2025 | $89.1K | -$2.2M | $-0.30 |
| Q1 2025 | $25.0K | -$2.2M | $-0.33 |
| Q3 2024 | $30.7K | -$1.1M | $-0.13 |
| Q2 2024 | $64.5K | -$2.2M | $-0.50 |
| Q1 2024 | $31.3K | -$2.2M | $-0.33 |
| Q3 2023 | $29.0K | -$2.9M | $-0.64 |
| Q2 2023 | $64.5K | -$3.0M | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BioRestorative Therapies, Inc. Dividends, Buybacks & Capital Allocation
BRTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioRestorative Therapies, Inc. (CIK: 0001505497)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BRTX
What is the AI rating for BRTX?
BioRestorative Therapies, Inc. (BRTX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BRTX's key strengths?
Claude: Exceptional gross margin of 93.5% suggests underlying product economics could be viable if revenue scales. Moderate debt-to-equity ratio of 0.11x indicates limited financial leverage and lower bankruptcy risk from debt obligations. ChatGPT: High gross margin indicates the limited revenue base is not constrained by direct production costs. Balance sheet leverage is low, with modest long-term debt relative to equity.
What are the risks of investing in BRTX?
Claude: Severe cash burn rate of -$8.4M operating cash flow against only $602.4K cash reserves indicates runway of approximately 2-3 months. Collapsing revenue (-35.7% YoY) combined with fixed operating costs creates deteriorating unit economics and path to insolvency. ChatGPT: Revenue declined 35.7% year over year, indicating weak and deteriorating commercial traction. Operating loss of $11.82M and free cash flow of -$8.41M are far too large relative to $602.44K cash on hand.
What is BRTX's revenue and growth?
BioRestorative Therapies, Inc. reported revenue of $340.1K.
Does BRTX pay dividends?
BioRestorative Therapies, Inc. does not currently pay dividends.
Where can I find BRTX SEC filings?
Official SEC filings for BioRestorative Therapies, Inc. (CIK: 0001505497) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BRTX's EPS?
BioRestorative Therapies, Inc. has a diluted EPS of $-1.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BRTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BioRestorative Therapies, Inc. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BRTX stock overvalued or undervalued?
Valuation metrics for BRTX: ROE of -500.0% (sector avg: 16%), net margin of -3,244.4% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy BRTX stock in 2026?
Our dual AI analysis gives BioRestorative Therapies, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BRTX's free cash flow?
BioRestorative Therapies, Inc.'s operating cash flow is $-8.4M, with capital expenditures of $36.4K. FCF margin is -2,472.9%.
How does BRTX compare to other Services stocks?
Vs Services sector averages: Net margin -3,244.4% (avg: 10%), ROE -500.0% (avg: 16%), current ratio 1.37 (avg: 1.5).